Related Experiment Video
Updated: Jan 17, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Identification of MAEA protein as a potential target for chemoresistance in osteosarcoma using bioinformatics and
Chen Zhang1, Ruizhen Wang2, Xin Yi3
1Department of Central Laboratory and Mitochondrial Medicine Laboratory, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China.
Introduction:
Osteosarcoma (OS) is the most common bone tumor, characterized by a high incidence, rapid progression, and frequent metastases. The implementation of chemotherapy has made important progress, while the necrosis rate is limited and the survival rates remain unsatisfactory, therefore novel approaches are needed.
Methods:
We used proteomic analysis to characterize the molecular landscape of patients exhibiting different levels of chemotherapy-induced necrosis.
Results:
Patients with low necrosis rate (≤70%) showed distinct expression patterns, with significant upregulation of proteins involved in DNA replication, metabolism, and mitochondrial pathway. The Runx1-related signaling pathway was also identified as potentially involved in disease progression. Remarkably, Mitochondrial Ribosomal Protein L4 (MRPL4) and Macrophage Erythroblast Attacher, E3 Ubiquitin Ligase (MEMA) were identified as hub proteins in MEGENA analysis and the public database. By integrating with immunohistochemistry, the higher expression level was verified in samples of OS patients compared to those of healthy people.
Discussion:
Overall, our project improves the knowledge of the expression pattern with different necrosis rates of OS samples, and the findings of MRPL4 and MAEA indicate the potential role in chemoresistance and provide new targets for the therapeutic strategy for OS patients with a low necrosis rate.
Insights
Osteosarcoma patients with low chemotherapy necrosis rates show distinct protein expression patterns. Mitochondrial Ribosomal Protein L4 (MRPL4) and Macrophage Erythroblast Attacher (MEMA) may offer new therapeutic targets for osteosarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Proteomics
Background:
- Osteosarcoma (OS) is a common bone cancer with poor survival rates despite chemotherapy.
- Current treatments have limited necrosis rates and unsatisfactory outcomes, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the molecular differences in osteosarcoma based on chemotherapy-induced necrosis levels.
- To identify potential biomarkers and therapeutic targets for osteosarcoma.
Main Methods:
- Proteomic analysis was employed to compare molecular profiles of patients with varying necrosis rates.
- Bioinformatic analysis (MEGENA) and immunohistochemistry were used to identify and validate hub proteins.
Main Results:
- Patients with low necrosis (≤70%) exhibited altered expression of proteins involved in DNA replication, metabolism, and mitochondrial pathways.
- The Runx1 signaling pathway was implicated in disease progression.
- Mitochondrial Ribosomal Protein L4 (MRPL4) and Macrophage Erythroblast Attacher (MEMA) were identified as key proteins with higher expression in OS patients.
Conclusions:
- This study enhances understanding of osteosarcoma molecular patterns related to necrosis.
- MRPL4 and MEMA show potential roles in chemoresistance and represent promising therapeutic targets for osteosarcoma.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
07:43Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
Published on: May 3, 2024
